- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Delcath Systems Inc (DCTH)
The Delcath Systems share price today is 10.840 %REPORT_CURRENCY%, view NASDAQ DCTH stock exchange data. Track the latest Delcath Systems share price with real-time updates on DCTH stock performance including market cap, day range, 52-week range and dividend yield. Access DCTH charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
10.500
10.900
52 wk Range
8.120
18.230
Earnings results expected in 12 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
10.50010.900
52 wk Range
8.12018.230
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DCTH Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
21.333
Upside
+96.80%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
- Form DEF 14A Delcath Systems For: 2 April
- Investing.com
- Form DEF 14A Delcath Systems For: 2 April
- Investing.com
- Form 13G DELCATH SYSTEMS For: 20 March
- Investing.com
- Form 8K Delcath Systems Inc For: 3 March
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
Delcath Systems Inc Earnings Call Summary for Q4/2025
- Q4 2025 revenue hit $20.73M, beating forecast by 3.19%; EPS of -$0.05 surpassed expected -$0.08 by 37.5%, though stock fell 6.46% in pre-market.
- Annual revenue reached record $85.2M in 2025; company achieved net income of $2.7M, reversing prior year's $26.4M loss with 85% gross margin.
- HEPZATO KIT sales surged 144% year-over-year, driving growth as company scales operations and expands product portfolio across treatment centers.
- Management projects Q1 2026 revenue of $23.5M and Q2 2026 revenue of $25.7M with EPS improving to $0.04 in Q2, signaling continued profitability trajectory.
- Key risks include potential market saturation, regulatory delays in treatment expansion, and revenue concentration in limited products amid seasonal demand patterns.
Last Updated: 26-02-2026, 08:16 pm
Read Full TranscriptCompare DCTH to Peers and Sector
Metrics to compare | DCTH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDCTHPeersSector | |
|---|---|---|---|---|
P/E Ratio | 138.3x | −7.2x | −0.5x | |
PEG Ratio | 1.29 | −0.16 | 0.00 | |
Price/Book | 3.4x | 4.5x | 2.6x | |
Price / LTM Sales | 4.4x | 3.7x | 3.2x | |
Upside (Analyst Target) | 84.6% | 56.7% | 47.4% | |
Fair Value Upside | Unlock | 12.4% | 7.7% | Unlock |
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 21.333
(+96.80% Upside)
Earnings
Latest Release
26-02-2026
EPS / Forecast
-0.05 / -0.08
Revenue / Forecast
20.73M / 20.09M
FAQ
What Is the Delcath Systems (DCTH) Share Price Today?
The Delcath Systems share price today is 10.840 USD.
What is the current Delcath Systems (DCTH) share price and day range?
As of 25-04-2026, the Delcath Systems share price is 10.840 USD, with a previous close of 10.640 USD. The share price has ranged from 10.500 to 10.900 USD today, while the 52-week range spans from 8.120 to 18.230 USD.
What Is the Delcath Systems Market Cap?
As of today, Delcath Systems market cap is 373.490M.
What Is the Delcath Systems (DCTH) Share Price Target?
The average 12-month share price target for Delcath Systems is 21.333 USD, with a high estimate of 30 USD and a low estimate of 18 USD. 6 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +96.80% Upside potential.
What Is Delcath Systems's Earnings Per Share (TTM)?
The Delcath Systems EPS (TTM) is 0.070.
When Is the Next Delcath Systems Earnings Date?
Delcath Systems will release its next earnings report on 07-05-2026.
From a Technical Analysis Perspective, Is DCTH a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Delcath Systems Trade On?
Delcath Systems is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Delcath Systems?
The stock symbol for Delcath Systems is "DCTH."
How Many Times Has Delcath Systems Stock Split?
Delcath Systems has split 5 times.
How Many Employees Does Delcath Systems Have?
Delcath Systems has 156 employees.
What Is the DCTH Premarket Price?
DCTH's last pre-market stock price is 10.720 USD. The pre-market share volume is 10.000, and the stock has changed by 0.080 USD, or 0.750%.
What Is the DCTH After Hours Price?
DCTH's last after hours stock price is 10.800 USD, the stock has changed by -0.040 USD, or -0.370%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.